Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Oxazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.68 |
| ▸ | CCKBR | P32239 | 4/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxazepam SCHEMBL29803925 | 1.00 | LMNA (1.00) | LMNAMEN1ALBKMT2APGR | |
| Oxazepam SCHEMBL27435 | 1.00 | LMNA (1.00) | LMNAMEN1ALBKMT2APGR | |
| Oxazepam SCHEMBL13746803 | 1.00 | LMNA (1.00) | LMNAMEN1ALBKMT2APGR | |
| Oxazepam SCHEMBL9614141 | 1.00 | LMNA (1.00) | LMNAMEN1ALBKMT2APGR | |
| Oxazepam SCHEMBL13746806 | 1.00 | LMNA (1.00) | LMNAMEN1ALBKMT2APGR | |
| Oxazepam SCHEMBL5498881 | 1.00 | LMNA (1.00) | LMNAMEN1ALBKMT2APGR | |
| Oxazepam SCHEMBL28100675 | 0.97 | LMNA (0.95) | LMNAMEN1ALBKMT2APGR | |
| Lorazepam SCHEMBL3695725 | 0.93 | LMNA (0.89) | LMNAMEN1ALBKMT2APGR | |
| SCHEMBL28348373 | 0.92 | LMNA (0.85) | LMNAMEN1ALBKMT2APGR | |
| Oxazepam SCHEMBL6680438 | 0.90 | LMNA (0.81) | LMNAMEN1ALBKMT2APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608146-A1 | USE FOR DELAYING GREENING AND/OR FORMATION OF SOLANINE IN POTATOES | Bayer Aktiengesellschaft (DE) | 2025-09-03 | — | — | EP | claimed |
| WO-2024088886-A1 | USE FOR DELAYING GREENING AND/OR FORMATION OF SOLANINE IN POTATOES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-02 | — | — | WO | claimed |
| US-20230102613-A1 | ADHESIVE LAYER, LAMINATE, OPTICAL LAMINATE, METHOD FOR PRODUCING OPTICAL LAMINATE, AND OPTICAL DEVICE | NITTO DENKO CORPORATION (JP) | 2023-03-30 | — | — | US | claimed |
| CN-114358562-A | Transient equivalence evaluation method for nuclear power plant primary circuit | 苏州热工研究院有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-107101989-A | Construction method based on Parameter adjustable control self-assembled structures substrate and its SERS detection methods for drugs | 安徽中科赛飞尔科技有限公司 | 2017-08-29 | — | — | CN | claimed |
| EP-2285365-A1 | USE OF A COMPOSITION COMPRISING AT LEAST ONE BETA-BLOCKER FOR THE TREATMENT OF SLEEP DISORDERS | Tullin, Søren (DK) | 2011-02-23 | — | — | EP | claimed |
| US-20110015261-A1 | USE OF A COMPOSITION COMPRISING AT LEAST ONE BETA-BLOCKER FOR THE TREATMENT OF SLEEP DISORDERS | Zleepax Europe ApS (DK) | 2011-01-20 | — | — | US | claimed |
| WO-2009018824-A1 | USE OF A COMPOSITION COMPRISING AT LEAST ONE BETA-BLOCKER FOR THE TREATMENT OF SLEEP DISORDERS | TULLIN SOEREN (DK) | 2009-02-12 | — | — | WO | claimed |
| EP-4729048-A1 | ORALLY DISPERSIBLE TABLETS OF OXAZEPAM | Neuraxpharm Pharmaceuticals, S.L. (ES) | 2026-04-22 | — | — | EP | disclosed |
| US-20260028502-A1 | RESIN COMPOSITIONS, POLYMERS MADE FROM THE RESIN COMPOSITION, METHODS OF MAKING THE POLYMER, AND METHODS AND SYSTEMS OF MAKING STRUCTURES THAT INCLUDE THE POLYMER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2026-01-29 | — | — | US | disclosed |
| WO-2025224480-A1 | BACKGROUND HEATER FOR HORIZONTAL OIL WELLS | GARCIA ROJAS, CHRISTIAN JAVIER (EC) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608146-A1 | USE FOR DELAYING GREENING AND/OR FORMATION OF SOLANINE IN POTATOES | Bayer Aktiengesellschaft (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-4572700-A | Elongated bendable drainage mat | MONSANTO COMPANY (US) | 1986-02-25 | — | — | US | disclosed |
| EP-0153926-A1 | MICRODROPLETS OF WATER-INSOLUBLE DRUGS. | HAYNES DUNCAN HAROLD | 1985-09-11 | — | — | EP | disclosed |
| WO-1985000011-A1 | MICRODROPLETS OF WATER-INSOLUBLE DRUGS | UNIV MIAMI (US) | 1985-01-03 | — | — | WO | disclosed |
| EP-0124500-A2 | Elongated bendable drainage mat | MONSANTO COMPANY (US) | 1984-11-07 | — | — | EP | disclosed |
| US-4331786-A | Moldable and/or extrudable polyether-ester-amide block copolymers | ATO CHIMIE (FR) | 1982-05-25 | — | — | US | disclosed |
| US-4156013-A | Method for treating patients suffering from anxiety neurosis and anxietylike neurosis, and alcoholism | ERASMUS UNIVERSITEIT ROTTERDAM (NL) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | LMNA 379/4885MEN1 3527/4885ALB 97/4885 |
| US-20260028502-A1 | RESIN COMPOSITIONS, POLYMERS MADE FROM THE RESIN COMPOSITION, METHODS OF MAKING THE POLYMER, AND METHODS AND SYSTEMS OF MAKING STRUCTURES THAT INCLUDE THE POLYMER | VCL, HTR3D, CAD | LMNA 3584/4885MEN1 4388/4885ALB 2094/4885 |
| US-20250171439-A1 | INDOLIN-2-ONE OR PYRROLO -PYRIDIN -2 -ONE DERIVATIVES | GRIN2B, HTR2B, HTR1A | LMNA 2606/4885MEN1 2090/4885ALB 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.